Debbie’s Dream Foundation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

DEBBIE’S DREAM FOUNDATION: Curing Stomach Cancer launched two research grants totaling $200,000 for the 2015-2016 grant cycle. A Career Development Award for $150,000 and a Young Fellowship Grant for $50,000 are being offered.

The grants will be administered by the American Association for Cancer Research. The DDF Gastric Cancer Fellowship Grant is geared toward postdoctoral and clinical researchers, while the Career Development Award is geared toward junior faculty who have completed their most recent doctoral degree or medical residency within the past eleven years. Both grants aim to involve those who conduct gastric cancer research and want to establish a successful career path in this field.

“For the third year in a row, we are thrilled to fund gastric cancer research. Each year we have doubled the amount award and the total we have authorized for research is $350,000,” said DDF President and Founder Debbie Zelman.

The grants are for basic, translational, and clinical research in stomach cancer and are available to scientists and clinicians at various career levels.

More information about the grants is available on the Debbie’s Dream website.

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login